Gansu Wuwei Heavy Ion Center

• National Tertiary Cancer Hospital
• China’s Top 100 Trusted Model Hospitals
• Home to China's First Carbon Ion Therapy System
• National Drug Clinical Trial Institution
• Management and operation of the Lanzhou Heavy Ion Campus, promoting the comprehensive development of the "Heavy Ion+" model in diagnosis, treatment, and industry sectors.
• The hospital has secured 1 national-level project from the Ministry of Science and Technology and 35 provincial-level projects from Gansu Department of Science and Technology and has received 30 scientific progress awards various industry accolades, with 208 national patents granted.
• Key Disciplines in Gansu Province: Gastroenterology and Radiotherapy; Key Disciplines in Wuwei City: Gastrointestinal Surgery, Thoracic Surgery, Gynecologic Oncology, etc.
• Team of internationally renowned heavy ion experts including Hirohiko Tsujii, Jörg Hauffe, Tatsuaki Kanai, Koichi Shibayama, and Koji Noda at the center.
• Equipped with advanced facilities such as PET-CT, 3.0T MRI, Dynamic 500-slice Gemstone Spectral CT, Siemens S2000 Color Ultrasound, VARIAN Vital Beam, and Elekta Infinity Linear Accelerator.
• The first domestic unit to clinically apply a self-developed heavy ion cancer treatment device, pioneering the 360° ion radiotherapy chair for comprehensive dynamic precision radiotherapy, having treated over 3000 patients from both domestic and international backgrounds.
• Implements the "Physiological-Psychological-Social Medicine" model, integrating comprehensive cancer treatment, traditional Chinese medicine health preservation, and full life-cycle health management.
• Features intelligent facilities including 5G unmanned shuttle buses, drug delivery robots, and track logistics systems.
• Commenced clinical operations in March 2020.

The Wuwei Heavy Ion Center, supported by the Institute of Modern Physics of the Chinese Academy of Sciences, commenced clinical operations in March 2020. Covering over 406 acres  with a total investment of CNY 3.2 billion, the center includes a 1,600-bed cancer hospital. Its carbon ion radiotherapy system, approved by the National Medical Products Administration (2019) and National Health Commission (2019), leverages advanced biological effects superior to X-rays and proton beams, enabling precise cancer targeting while sparing healthy tissues.

The Wuwei Heavy Ion Treatment System received approval from the National Medical Products Administration on September 29, 2019. The carbon ion radiotherapy system configuration license was approved by the National Health Commission on November 29, 2019.

Professional technical personnel have undergone training at institutions in Germany, the United States, Japan, and the Shanghai Proton and Heavy Ion Hospital, acquiring the latest knowledge related to heavy ions.

The Wuwei Cancer Hospital of Gansu Province has established medical alliances with multiple domestic cancer hospitals. Carbon ion beams are characterized by their heavier particle mass compared to X-rays and proton beams, providing a more reasonable dose distribution within the human body compared to X-ray and proton beams. This allows for effective cancer treatment without harming other important normal tissues. In addition, the carbon ion beam offers superior biological effects and can be effective against tumors that are refractory to X-ray and proton beams. The center simultaneously incorporates precision nuclear medicine for diagnosis and treatment, establishing a dual-pathway precision oncology system that combines external heavy-ion radiotherapy with targeted internal radionuclide therapy.

The Wuwei Heavy Ion Center is committed to becoming a first-class domestic institution with internationally advanced standards, integrating heavy ion basic research, talent cultivation, and clinical treatment into a comprehensive industrial, educational, and research center for cancer diagnosis and treatment. In the future, heavy ion beam therapy is poised to play a more significant role, offering the best possible radiation therapy for cancer patients.